Tromsø, Norway, 16th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) launches AZscript™ Reverse Transcriptase ArcticZymes Technologies (AZT) today announces the launch of its new product AZscript™ Reverse Transcriptase (RT). Launching the AZscript™ RT product is a natural expansion of the Company’s molecular tools portfolio. Reverse transcriptases are critical enzymes for molecular diagnostics and are used to convert RNA into DNA …
Tromsø, Norway, 9th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) upscales the production of ArcticZymes Proteinase and launches ArcticZymes Proteinase Glycerol FREE ArcticZymes Technologies (AZT) has successfully upscaled the production of ArcticZymes Proteinase. This will allow the Company to meet growing demand from new and existing customers, thereby strengthening the Company´s position as a supplier of critical components in …
Tromsø, Norway, 08th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) exclusively licenses novel DNA assembly technology from UiT The Arctic University of Norway ArcticZymes Technologies (AZT) has signed an exclusive licensing agreement with UiT The Arctic University of Norway (UiT) for a novel DNA assembly technology. The technology was developed by researchers at UiT and is based on unique …
ArcticZymes Technologies is attending the MEDICA 2022 at the Messe Düsseldorf, Germany from 14-17 November. Kees Linschooten, Senior Business Development Manager, Helge Lind, Ph.D., Senior Market Development Manager, and Dirk Hahneiser VP of Business Development and Marketing are looking forward to meeting you at the Diagnostic Hall 3, booth # J26 for a discussion on our enzyme solutions for sensitive, …